EP2832358A1 — Pharmaceutical kit for use in the treatment of colon and colorectal cancer
Assigned to Bionsil SRL · Expires 2015-02-04 · 11y expired
What this patent protects
The present invention describes therapies for the effective treatment of colon and colorectal carcinomas. The present invention relates to a pharmaceutical kit comprising ibrutinib and fluorouracil, for the treatment of colon and colorectal carcinomas also in the case in which su…
USPTO Abstract
The present invention describes therapies for the effective treatment of colon and colorectal carcinomas. The present invention relates to a pharmaceutical kit comprising ibrutinib and fluorouracil, for the treatment of colon and colorectal carcinomas also in the case in which such carcinomas are drug resistant and therefore allows to overcome cancer drug resistance.
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.